Skip to Content

FDA rejects psychedelic MDMA as treatment for PTSD, calling for additional study

KIFI

AP Health Writer

WASHINGTON (AP) — Federal health officials have declined to approve the psychedelic drug MDMA as a therapy for PTSD. Drugmaker Lykos Therapeutics announced the FDA’s decision on Friday. Supporters of psychedelic therapy hoped that MDMA would make history as the first illegal psychedelic to win FDA approval, paving the way for similar drugs to enter the medical mainstream. But FDA’s rejection was widely expected after a negative review of the drug in June. Government advisers voted overwhelmingly against the drug, citing questionable study data and allegations of research misconduct.

Article Topic Follows: AP National

Jump to comments ↓

Author Profile Photo

Associated Press

BE PART OF THE CONVERSATION

KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content